BETAMETHASONE DIPROPIONATE
Clinical safety rating: avoid
Live vaccines should not be given concurrently Phenytoin phenobarbital and rifampin reduce corticosteroid effects Systemic effects can occur with extensive topical use.
Betamethasone dipropionate is a glucocorticoid receptor agonist that binds to cytosolic glucocorticoid receptors, leading to modulation of gene transcription. It suppresses pro-inflammatory cytokines (e.g., IL-1, IL-2, TNF-α), inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes mast cells.
| Metabolism | Primarily hepatic via CYP3A4; forms inactive metabolites (e.g., 6β-hydroxybetamethasone). |
| Excretion | Renal, ~75% as conjugated metabolites; biliary/fecal, ~25%. |
| Half-life | Terminal elimination half-life: 6-8 hours (parenteral); clinically, duration of adrenal suppression may extend beyond this. |
| Protein binding | 64-84% bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | 0.6-0.8 L/kg; reflects moderate tissue distribution. |
| Bioavailability | Intra-articular: near 100%; intramuscular: 100%; topical: <1% systemically absorbed through intact skin, up to 36% via inflamed or damaged skin. |
| Onset of Action | Intra-articular: 2-6 hours; intramuscular: 6-24 hours; topical: days to weeks for dermatologic effect. |
| Duration of Action | Intra-articular: 1-3 weeks; intramuscular: 4-6 weeks; topical: varies by formulation and lesion; single dose may suppress cortisol for 2-4 weeks. |
Apply topically as 0.05% cream, ointment, or lotion to affected area once or twice daily. Maximum: 45 g/week.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required for topical use. For systemic absorption, caution in severe renal impairment. |
| Liver impairment | No dosage adjustment required for topical use. For systemic absorption, consider reduced dose in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Apply sparingly; limit to smallest amount for effective treatment. Avoid prolonged use, occlusion, and use on face or intertriginous areas. Safety in children under 2 years not established. |
| Geriatric use | Use with caution due to increased susceptibility to skin thinning. Apply minimally and avoid occlusive dressings. Monitor for systemic effects with prolonged use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Live vaccines should not be given concurrently Phenytoin phenobarbital and rifampin reduce corticosteroid effects Systemic effects can occur with extensive topical use.
| FDA category | Positive |
| Breastfeeding | Betamethasone is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.9 based on betamethasone data. For dipropionate, minimal systemic absorption expected. Use with caution, especially with high doses. Consider waiting 3-4 hours after dose to breastfeed. |
| Teratogenic Risk |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Hyperglycemia |
| Serious Effects |
["Hypersensitivity to betamethasone or any component","Untreated bacterial, fungal, viral, or parasitic skin infections","Perioral dermatitis","Rosacea","Application to broken or compromised skin"]
| Precautions | ["HPA axis suppression with prolonged use or large surface area application","Systemic effects including Cushing's syndrome, hyperglycemia, and osteoporosis","Local adverse reactions: skin atrophy, striae, telangiectasia, acneiform eruptions","Increased risk of infections; avoid use on infected lesions unless appropriate antimicrobial therapy is given","Rebound dermatitis upon abrupt discontinuation"] |
| Food/Dietary | No clinically significant food interactions have been reported for topical betamethasone dipropionate. Systemic absorption is minimal with proper topical use, so dietary restrictions are not required. |
Loading safety data…
| Betamethasone dipropionate is a corticosteroid. In the first trimester, limited human data; animal studies show increased risk of cleft palate. In second trimester, associated with intrauterine growth restriction (IUGR) and adrenal suppression. In third trimester, used for fetal lung maturity but may cause transient neonatal adrenal suppression. Overall, benefits may outweigh risks with appropriate monitoring. |
| Fetal Monitoring | Maternal: blood pressure, blood glucose, signs of infection, adrenal function. Fetal: ultrasound for growth (IUGR), fetal heart rate monitoring, assessment for preterm labor. Neonatal: monitor for adrenal insufficiency after delivery. |
| Fertility Effects | Not known to directly impair fertility. High doses may disrupt menstrual cycles or reduce sperm count in animal studies. Clinical significance in humans is unclear. |
| Clinical Pearls | Betamethasone dipropionate is a high-potency topical corticosteroid used for inflammatory and pruritic dermatoses. Absorption can be significant when applied to large areas or under occlusion, leading to systemic effects like HPA axis suppression. Avoid use on face, groin, or axillae due to risk of atrophy. Not recommended for diaper dermatitis. Monitor for local infections; antifungal/antibacterial may be needed. Use for short courses (2 weeks) and taper dose. In psoriasis, intermittent dosing can reduce relapse. Betamethasone dipropionate is the 17,21-dipropionate ester, enhancing potency and penetration. |
| Patient Advice | Apply a thin layer to the affected skin areas only; do not use on open wounds or broken skin. · Avoid covering the area with bandages or wraps unless directed, as this increases absorption and risk of side effects. · Do not use on your face, groin, or armpits unless specifically instructed by your doctor, as these areas are more susceptible to side effects. · Wash hands after applying, unless treating hands. · Use the medication exactly as prescribed; do not use more often or for longer than recommended to prevent systemic effects. · Inform your doctor if you develop signs of skin infection (increased redness, swelling, pus) or if your condition does not improve after 2 weeks. · Avoid getting the medication in your eyes or mouth. If contact occurs, rinse thoroughly with water. |